Modulation of the hypothalamic-pituitary-adrenal-adipose axis with leptin receptor ligands
CA 2282341 A1 · Owner: Eli Lilly And Company · Inventors: Stephens, Thomas W.; Caro, Jose F.; Craft, Libbey S.
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
This invention relates generally to a method for modulating the Hypothalamic- Pituitary-Adrenal Adipose Axis (HPAAA) in a mammal in need of such treatment by administration of a therapeutically effective amount of a leptin receptor ligand. More specifically, this invention relates to the use of leptin receptor agonists to treat disorders of the HPAAA including the , hyperglucocorticoidemia associated with Cushing's Syndrome fasting, or , otherwise-induced stress in obese or lean mammals in need of such treatment. This invention also relates to the use of leptin receptor antagonists or , specific anti-leptin antibodies, to treat the hypoglucocorticoidemia associated with autoimmune or …
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed February 24, 1998. No grant is recorded for it in Canada; had it been granted, its 20-year term would have ended February 24, 2018.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by February 24, 2020.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.